Zhejiang Xianju Pharmaceutical Co.,Ltd. announced that it has received CNY 999.99999 million in funding from a group of investors

On October 30, 2020, Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332) closed the transaction. The company amended the terms of the transaction. The company issued 72,992,700 shares at CNY 13.70 per share for gross proceeds of CNY 999,999,990.

The transaction included participation from Xianju State-Owned Assets Investment Group Co. Limited for CNY 431,098,009.6, Li Qinjian for CNY 299,999,997, HFT Investment Management Co., Ltd. (SHSE:511270) for CNY 193,999,973.4, Luo Xiangchun for CNY 141,999,979.4, Fan Minhua for CNY 139,999,998.6, Huatai Asset Management Co., Ltd. for CNY 119,999,998.8, China Merchants Fund Management Co.,Ltd. for CNY 109,999,985.2, Hualu Investment Development Co., Ltd. for CNY 49,999,999.50, JT Asset Management Co., Ltd for CNY 46,999,987.20, SUNON Investment Management Co., Ltd. for CNY 34,999,992.80, Li Jianhua for CNY 32,999,998.30, Shenzhen Zhaoyin Dinghong Investment Management Co., Ltd. for CNY 30,999,990.10, Lukang Investment Co., Ltd. for CNY 29,999,999.70, Taikang Asset Management Co., Ltd. for CNY 29,999,999.70, Caitong Fund Management Co., Ltd. for CNY 25,451,051.70. The company paid securities registration & other fees of CNY 589,347.12.